Letter to the editor: Trimetazidine and allopurinol for the prevention of contrast-associated acute kidney injury in elective percutaneous coronary intervention: a randomized controlled trial

Authors

• Elsayed Balbaa, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
• Ameer Awashra, Department of Medicine, An-Najah National University, P.O. Box 7, Old Campus Street 7, Nablus, Palestine. [email protected].
• Mohamed Saad Rakab, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, College of Medicine, University of Illinois Chicago, Chicago, IL, United States.
• Mohamed S. Elgendy, Faculty of Medicine, Tanta University, Tanta, Egypt.
• Belal Mohamed Hamed, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
• Abdalhakim Shubietah, Advocate Health - MidwestFollow

Recommended Citation

Balbaa E, Awashra A, Rakab MS, Elgendy MS, Hamed BM, Shubietah A. Letter to the editor: Trimetazidine and allopurinol for the prevention of contrast-associated acute kidney injury in elective percutaneous coronary intervention: a randomized controlled trial. Eur J Clin Pharmacol. 2026;82(11):264. Published 2026 Oct 5. doi:10.1007/s00228-026-04195-4

Affiliations

Advocate Illinois Masonic Medical Center

Type

Article

PubMed ID

42831894